Phase II trial of tumour infiltrating lymphocytes in patients with metastatic melanoma
Phase of Trial: Phase II
Latest Information Update: 27 Jun 2017
At a glance
- Drugs LN 144 (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors Iovance Biotherapeutics; Lion Biotechnologies Inc
- 27 Jun 2017 According to an Iovance Biotherapeutics media release, Lion Biotechnologies has changed its name to Iovance Biotherapeutics.
- 16 Sep 2015 According to a Lion Biotechnologies media release, updated results from this trial were presented at the American Association for Cancer Research Inaugural International Cancer Immunotherapy Conference.
- 16 Sep 2015 Updated results from this trial were published in a Lion Biotechnologies media release.